skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

About Ian

Japan

33+ years of experience

Ian Haydock | Pharma Intelligence
Ian oversees content for the Asia-Pacific area, including in the commercial and policy/regulation areas, with a particular interest in company and pricing topics. He has been covering the region for more than 20 years as a writer and editor in the pharma sector.
Ian first moved to Japan in the 1990s and has covered a broad range of pharma industry topics, both across this market and the rest of Asia, including corporate, R&D, pricing and policy developments. After a stint as a Tokyo-based Japan and Asia editor for Scrip, he became managing editor of PharmAsia News (now part of Scrip/Pink Sheet) in 2014, and is a recipient of multiple Informa internal awards. He has a long personal and professional background in Asia, having grown up in Hong Kong, and follows regional regulatory harmonization and trade initiatives with interest. Ian lives in Tokyo with his wife and two sons.

Analyst Articles

Articles by Ian

  • Scrip

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 04 Oct 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: the prospects for Merck’s Acceleron acquisition; the pandemic and biotech capital in-flow; an interview with Menarini’s CEO; upcoming endocrine and metabolic product disorders; and an interview with Novartis Pharma’s president.

  • Scrip

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 26 Sep 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: an interview with the president of Novartis Pharma; Biogen highlights its pipeline; standout comparative data for Enhertu in breast cancer; Sanofi/Regeneron nip at Keytruda’s heels in first-line lung cancer; and a look at the market prospects for wet AMD.

  • Scrip

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 06 Sep 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: new US warnings for JAK inhibitors; strong new heart failure results for Jardiance; good head-to-head results for Pfizer in atopic dermatitis; US payers and drug exclusion lists; and a look ahead at key expected hematology launches.  

  • Scrip

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 16 Aug 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: a history of Alzheimer’s drug development; BioNTech looks beyond COVID-19 vaccines; gene therapy setbacks for bluebird; new promise for Roche’s Polivy in B-cell lymphoma; and rising US momentum for US drug price negotiations.

  • Scrip

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 09 Aug 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: AstraZeneca looks to return to normality; Bayer’s hopes for Kerendia; Novartis’s plans for a new version of Zolgensma; Arcturus benefits from mRNA interest; and AbbVie changes tack in Alzheimer’s.

  • Scrip

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 25 Jul 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: J&J’s outlook for coronavirus vaccines; Cosentyx comes in strong for Novartis; Biogen’s views on Aduhelm pricing; competition in the “dustat” sector; and dealing with endemic COVID-19.

  • Scrip

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 05 Jul 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: vaccine efficacy and the Delta and Delta Plus variants; breakthroughs in CRISPR gene editing and microbiome therapies; and the pandemic’s possible effect on regulatory pathways.

  • Scrip

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 27 Jun 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: a look at pharma CEO pay; Pfizer’s CEO gives the inside track on COVID vaccine development; GSK elaborates on its restructuring and strategic plans; and Kite talks about its cell therapy plans under Gilead. 

  • Scrip

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 20 Jun 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Scrip's Five Must-Know Things: new developments in the TIGIT field; doctor frustration over Aduhelm guidance; are pediatric COVID vaccines necessary: the battle of the SERDs; and one Indian firm’s plans for lung disease leadership.

  • Scrip

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 13 Jun 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast edition of Five Must-Know Things: a ground-breaking approval for Alzheimer’s in the US; LAG-3 inhibitors and new Keytruda data generate excitement at ASCO; and clinical progress for another COVID-19 vaccine.

  • Scrip

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 23 May 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast episode of Five Must-Know Things, hear about GSK coming under pressure from investors; BMS focusing on a promising oncology target in a new deal; Sanofi’s COVID-19 vaccine challenges; China's progress with mRNA coronavirus vaccines; and new headwinds for Pfizer’s Ibrance.

  • Scrip

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 20 Apr 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast version of Five Must-Know Things, hear about adenovirus vaccines and blood clots, Lilly’s new moves in genetic diseases, the efficacy debate over Chinese COVID-19 vaccines, putting a price tag on innovation, and Sanofi’s bullishness on IL-2.

  • Scrip

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 11 Apr 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast version of Five Must-Know Things, hear about whether safety concerns may affect JAK inhibitors, Takeda’s strategic R&D plans, Cigna’s psoriasis insurance program, Phase III readouts to look for, and an overview of the global pharma R&D pipeline.

  • Scrip

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 21 Mar 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast version of Five Must-Know Things, hear about new results for Lilly in Alzheimer’s, a US delay for AbbVie, progress for Zolgensma in the UK, challenges for AstraZeneca’s coronavirus vaccine, and a Scrip roundtable on industry lessons from the pandemic.

  • Scrip

    Quick Listen: Scrip’s Five Must-Know Things

    By Ian Haydock 15 Mar 2021

    SC2008_FiveMustKnowThings_1200_Final

    In this week's podcast version of Five Must-Know Things, hear about Roche's deal-making in a pandemic, coronavirus vaccine disinformation, Amgen’s Five Prime acquisition, a Novartis clinical trial failure, and new data for a Merck antiviral for the coronavirus.